Identification Of Ape1 As A Novel Prognostic Factor And Possible Therapeutic Target For Advanced Nsclc Patients Receiving Platinum-Based Doublet Chemotherapy.

e22061 Background: Although platinum-based doublet chemotherapy is the most common therapeutic regime for advanced non-small-cell lung cancer (NSCLC) patients, a substantial proportion of patients are resistant to platinum-based chemotherapy. ERCC1 is the most recognized predictive biomarker for response to platinum-based chemotherapy, but a recent study revealed that ERCC1 is not an ideal predictive marker. DNA repair capacity has been established as an important factor responsible for the cellular response to platinum treatment, and APE1, a critical DNA repair enzyme, has been linked to intrinsic resistance to platinum. Methods: The protein levels of ERCC1 and APE1 of 172 NSCLC patients were evaluated by immunohistochemistry (IHC) and their correlation with response rate to platinum-containing chemotherapy, progress-free survival (PFS) and overall survival (OS) was analyzed. The involvement of APE1 in cellular response to platinum treatment and possible synergistic effects with ERCC1 inhibition were con...